Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.

MLA

Guzelant, Gul, et al. “Infliximab for Uveitis of Behçet’s Syndrome: A Trend for Earlier Initiation.” Clinical and Experimental Rheumatology, vol. 35 Suppl 108, no. 6, Nov. 2017, pp. 86–89. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=29148418&authtype=sso&custid=ns315887.

APA

Guzelant, G., Ucar, D., Esatoglu, S. N., Hatemi, G., Ozyazgan, Y., Yurdakul, S., Seyahi, E., Yazici, H., & Hamuryudan, V. (2017). Infliximab for uveitis of Behçet’s syndrome: a trend for earlier initiation. Clinical and Experimental Rheumatology, 35 Suppl 108(6), 86–89.

Chicago

Guzelant, Gul, Didar Ucar, Sinem Nihal Esatoglu, Gulen Hatemi, Yilmaz Ozyazgan, Sebahattin Yurdakul, Emire Seyahi, Hasan Yazici, and Vedat Hamuryudan. 2017. “Infliximab for Uveitis of Behçet’s Syndrome: A Trend for Earlier Initiation.” Clinical and Experimental Rheumatology 35 Suppl 108 (6): 86–89. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=29148418&authtype=sso&custid=ns315887.